Co-Administration of Nitric Oxide-Aspirin (NCX-4016) and Aspirin Prevents Platelet and Monocyte Activation and Protects Against Gastric Damage Induced by Aspirin in Humans
- 5 August 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 44 (3) , 635-641
- https://doi.org/10.1016/j.jacc.2004.03.079
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- NCX-4016 (NO-Aspirin) Inhibits Lipopolysaccharide-Induced Tissue Factor Expression In VivoCirculation, 2002
- Inflammation in atherosclerosisNature, 2002
- Essential Role of Monocyte Chemoattractant Protein-1 in Development of Restenotic Changes (Neointimal Hyperplasia and Constrictive Remodeling) After Balloon Angioplasty in Hypercholesterolemic RabbitsCirculation, 2002
- NCX4016 (NO‐Aspirin) has multiple inhibitory effects in LPS‐stimulated human monocytesBritish Journal of Pharmacology, 2001
- Nitrovasodilators, Low-Dose Aspirin, Other Nonsteroidal Antiinflammatory Drugs, and the Risk of Upper Gastrointestinal BleedingNew England Journal of Medicine, 2000
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Tissue Factor Modulates the Thrombogenicity of Human Atherosclerotic PlaquesCirculation, 1997
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.Journal of Clinical Investigation, 1995
- Suppression of Thromboxane A2but Not of Systemic Prostacyclin by Controlled-Release AspirinNew England Journal of Medicine, 1991